1,858
Participants
Start Date
December 15, 2016
Primary Completion Date
August 31, 2023
Study Completion Date
January 10, 2024
Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
Intravenous Tenecteplase
IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
Queen Elizabeth University Hospital, Glasgow
University of Glasgow
OTHER
University of Edinburgh
OTHER
Oxford University Hospitals NHS Trust
OTHER
NHS Greater Glasgow and Clyde
OTHER